Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Century Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$83.40M. For fiscal 2025 it was -$103.88M. The highest annual figure on record is $14.05M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$103.88M | – |
| FY2024 | Dec 31, 2024 | -$110.14M | – |
| FY2023 | Dec 31, 2023 | -$88.35M | -728.7% |
| FY2022 | Dec 31, 2022 | $14.05M | – |
| FY2021 | Dec 31, 2021 | -$89.00M | – |
| FY2020 | Dec 31, 2020 | -$41.27M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$22.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.83M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.22M | -133.7% |
| Q4 FY2022 | Dec 31, 2022 | -$22.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.24M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.56M | – |
| Q1 FY2022 | Mar 31, 2022 | $86.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.23M | – |
See a number that looks wrong?